TuHURA Biosciences (HURA) investor relations material

Executive summary

• Q3 2026 net loss was $6.4M vs. $7.1M YoY; nine-month net loss was $23.2M vs. $23.3M.

• Cash and cash equivalents were $1.9M at September 30, 2026; available resources, including anticipated Parkview facility proceeds, were expected to fund planned operations into 2028.

• IFX-2.0 plus Keytruda produced major objective partial responses in the first 3 patients with deep-seated metastatic Merkel cell carcinoma; all remained ongoing for more than 6 months.

• FDA cleared a Phase 1b study of TBS-2025 in relapsed/refractory mutNPM1 AML.

Financial highlights

• Q3 R&D expense was $3.7M vs. $5.0M YoY, mainly due to lower manufacturing costs; G&A was $2.0M vs. $1.6M, and operating loss was $5.7M vs. $6.7M.

• Nine-month R&D was $15.6M vs. $14.5M and G&A was $6.4M vs. $5.5M; 2025 included $3.7M of Kineta merger-related costs.

• No product revenue was generated; nine-month operating cash use was $18.1M vs. $22.1M in 2025.

Outlook and guidance

• IFX-2.0 Phase 3 topline results are anticipated in H2 2027; preliminary front-line study results are expected in 1H 2027, with Phase 3 enrollment completion expected in 2H 2027.

• TBS-2025 Phase 1b/2 initiation in mutNPM1 AML was expected in 2H 2026; preliminary safety and response data and AML orphan drug designation were expected in 1H 2027.

• DOR research presentations at ASH and ADC in-vivo proof-of-concept studies were expected in 2H 2026.

• R&D spending is expected to increase as clinical and preclinical programs advance; timing, costs and outcomes remain uncertain.